XJPX

2183

Market cap28mUSD

Oct 09, Last price

200.00JPY

-0.99%

-5.66%

Jan 2017

-84.11%

IPO

-34.43%

Name

Linical Co Ltd

Chart & performance

D1W1MN

P/E

—

P/S

0.52

EPS

—

Div yield, %

7.92%

Shrs. gr., 5y

—

Rev. gr., 5y

-3.36%

Revenues

8.67b

-16.97%

Net income

-3.33b

L+517.61%

CFO

-1.52b

Dividend

Mar 30, 20278 JPY/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Linical Co., Ltd., a global contract research organization provides full spectrum of drug development services to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariats; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.

Key people

Kazuhiro Hatano

President, Chief Executive Officer, Chief Commercial Officer, Chief Strategy Officer, Executive Officer, Chief Director of Development, Manager of Sales Planning Office, Representative Director · since 2024

Akihiro Takahashi

Executive Officer, Chief Financial Officer, Manager of Accounting & Finance Unit · since 2024

Toshiaki Nagafuji

Executive Officer, Chief Technical Officer, Director of Drug Discovery Support in Main Development Unit · since 2024

Jun Kawai

Executive Officer, Chief Administrative Officer, Deputy Chief Director of Administration, Manager of General Affairs, Human Resources and Legal Affairs Unit · since 2024

Shiori Yamaguchi

Executive Officer, Chief Compliance Officer, Manager of Audit Office · since 2024

Tomoko Inomata

Executive Officer, Director of Primary Area Business in Main Development Unit · since 2024

Masaya Miyazaki

Executive Officer, Chief Asia Pacific Officer · since 2024

Tatsuya Shiraishi

Executive Officer · since 2024

Yushi Tajima

Executive Officer · since 2023

Masayoshi Tokuno

Executive Officer, Chief Information Officer, Manager of Global IT Strategy Office · since 2024

Satoru Toyoda

Executive Officer, Director of Oncology Business in Main Development Unit · since 2024

Keigo Tsujimoto

Executive Officer, Chief Project Officer, Director of Project Management Business · since 2024

Yoshimitsu Ando